Beatrice Suero
Associate Director, HEOR
Expertise:
Beatrice has experience in all aspects of HEOR, including indirect treatment comparisons, economic modelling, systematic literature reviews, and RWE.
In her four years with EVERSANA, Beatrice has established herself as an expert in reimbursement strategies and has successfully supported multiple Canadian and Global reimbursement submissions.
Beatrice serves as a vital conduit within HTA submissions, seamlessly integrating statistical analyses with economic modelling to build a cohesive and robust pharmacoeconomic strategy. Her role is crucial in synthesizing HEOR elements to develop a harmonized approach for submission strategies.
Beatrice specializes in systematic literature reviews, development and adaptation of cost-effectiveness and budget impact, and indirect treatment comparisons (e.g., network meta-analyses, matching-adjusted indirect comparisons).
Prior to joining EVERSANA, Beatrice earned an MSc degree in Epidemiology and Biostatistics from Queen’s University, where she gained experience in data analytics.
Articles by Beatrice Suero
Real-World Insights: Effectiveness and Safety of Crizotinib in ROS1-Rearranged NSCLC
Lung cancer is one of the most incident malignancies and the leading cause of cancer death worldwide. Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer cases and, with the emergence of genomic techniques, tumor genotyping has led to the identification of actionable driver alterations in NSCLC. The ROS1 gene encodes a tyrosine kinase receptor that plays an important role in the activation of several signaling pathways associated with cellular differentiation, proliferation, growth and survival. ROS1 gene rearrangement is rare and is detected as an oncogenic driver in 0.9% to 2.6% of NSCLC cases. Crizotinib was first approved for ROS1 advanced NSCLC (aNSCLC) in the United States in […]